Bibliographic Details
| Title: |
Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment. |
| Authors: |
Hafez Ghoran, Salar1,2 (AUTHOR) s_hafezghoran@yahoo.com, Calcaterra, Andrea3 (AUTHOR), Abbasi, Milad4 (AUTHOR), Taktaz, Fatemeh5,6 (AUTHOR), Nieselt, Kay7 (AUTHOR), Babaei, Esmaeil7,8 (AUTHOR) s_hafezghoran@yahoo.com |
| Source: |
Molecules. Aug2022, Vol. 27 Issue 16, p5236-5236. 29p. |
| Subject Terms: |
*ADJUVANT treatment of cancer, *CURCUMIN, *TURMERIC, *POISONS |
| Geographic Terms: |
UNITED States |
| Abstract: |
Throughout the United States, cancer remains the second leading cause of death. Traditional treatments induce significant medical toxic effects and unpleasant adverse reactions, making them inappropriate for long-term use. Consequently, anticancer-drug resistance and relapse are frequent in certain situations. Thus, there is an urgent necessity to find effective antitumor medications that are specific and have few adverse consequences. Curcumin is a polyphenol derivative found in the turmeric plant (Curcuma longa L.), and provides chemopreventive, antitumor, chemo-, and radio-sensitizing properties. In this paper, we summarize the new nano-based formulations of polyphenolic curcumin because of the growing interest in its application against cancers and tumors. According to recent studies, the use of nanoparticles can overcome the hydrophobic nature of curcumin, as well as improving its stability and cellular bioavailability in vitro and in vivo. Several strategies for nanocurcumin production have been developed, each with its own set of advantages and unique features. Because the majority of the curcumin-based nanoformulation evidence is still in the conceptual stage, there are still numerous issues impeding the provision of nanocurcumin as a possible therapeutic option. To support the science, further work is necessary to develop curcumin as a viable anti-cancer adjuvant. In this review, we cover the various curcumin nanoformulations and nanocurcumin implications for therapeutic uses for cancer, as well as the current state of clinical studies and patents. We further address the knowledge gaps and future research orientations required to develop curcumin as a feasible treatment candidate. [ABSTRACT FROM AUTHOR] |
|
Copyright of Molecules is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
